This aggressive metabolic shift, while beneficial for fat loss, places demands on the body that warrant additional support
Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk
Additionally, while Ozempic off-label use is growing, its vital to consult healthcare providers about the potential for adverse events and ensure any weight loss medication is used in the context of a comprehensive care plan
History of pancreatitis Severe gastrointestinal disease Gallbladder disease or a history of cholelithiasis Pregnancy or breastfeeding Concomitant use of insulin or insulin secretagogues (e.g., sulphonylureas), which may increase hypoglycaemia risk Retatrutide, like other incretin-class medicines, may slow gastric emptying, which can affect the absorption of oral medicines taken at the same time
Weeks 8-12 : More significant improvements in deeper wrinkles, continued collagen density increase, improved skin thickness (measured via ultrasound in clinical settings), and sustained reduction in age-related skin laxity